Background: Gastric cancer-related deaths are among the leading causes of cancer-related deaths. Clinical trials with targeted agents continue in the treatment of stomach cancer, with randomized trials of chemotherapy to prolong survival in the treatment of metastatic gastric cancer. Metastatic stomach cancer treatment is also becoming increasingly personalized to the characteristics of the patient and tumor as it is in breast cancer.
Result: Trastuzumab has shown randomized trial (TOGA study) in c-erbB2 positive metastatic stomach and gastroesophageal junction adenocancer patients to prolong median survival.Immunohistochemically, the presence of cerbB2 positivity and scoring at the time of diagnosis or in the resection material suggests that patients, especially in the metastatic stage, is necessary. The grade (score) of Cebb2 positivity was more pronounced in adenocarcinomas especially located anatomically close to the gastroesophageal junction.
Conclusion: In our study, it was aimed to reveal the relationship between the demographic characteristics of patients who are candidates for treatment and the level of cerbB2 positivity and anatomic localization, especially in the metastatic stage if stomach and thyroid cancer are considered to be a common condition in our region.
Bangladesh Journal of Medical Science Vol.18(1) 2019 p.124-129
Background: In spite of resistance and limited response to chemotherapy, radiotherapy and immunotherapy, recent advances led to several targeted agents that showed the prolongation of progressive free survival. Due to these facts, surgical resection of multiple recurrences may be worthwhile in selected patients with kidney cancer. Case Report: We report a case of a 47-year-old man who underwent nephrectomy for T4N0 RCC, clear cell type, Fuhrman grade 2/4 in 2007. The patient afterward had multiple tumor recurrences. He underwent four metastasectomies, including liver, skin, rectum and scalp. And he received immunotherapy and multiple lines biological targeted treatments. He remains stable for 7 years after initial diagnosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.